Viatris sues Novo over a Wegovy patent, but the complaint shows a narrow fight, not a generic launch

Viatris unit Mylan Pharmaceuticals has asked a federal court in Delaware to declare that its proposed generic version of Novo Nordisk's weight-loss drug Wegovy does not infringe one of Novo's patents, and that the patent is invalid. Seeking Alpha summed it up as Viatris seeking "to market generic Wegovy." Novo earned nearly $31 billion from its semaglutide drugs Wegovy and Ozempic last year, Reuters reported.

The headline makes it sound as if a cheap Wegovy is close. The complaint itself, filed on Sept. 23 as case 1:26-cv-01192, describes something much narrower.

What the lawsuit is actually about

• One patent, issued this year. The target is U.S. Patent No. 12,551,536, "Semaglutide in Medical Therapy," which the complaint says was issued on Feb. 17, 2026. It claims a method of reducing body weight by injecting 2.0 to 10.0 mg of semaglutide weekly.
• Listed for one pen only. Novo listed the patent in the FDA's Orange Book only for the 2.4 mg Wegovy pen. Mylan's application, ANDA No. 217705, covers all five strengths, from 0.25 mg to 2.4 mg.
• Novo let a deadline pass. Mylan sent notice on June 17 that it was challenging the patent, and Novo received it on June 18 and 19. The law gives a brand company 45 days to sue. Novo did not, which let Mylan sue first to remove the patent as an obstacle. Without that, the complaint says, the unasserted patent "may impair Mylan's ability to market" its product.
• The main fight is elsewhere. The complaint says Novo is already suing Mylan over the same application in a separate case (No. 23-101-CFC), asserting a related patent, No. 12,029,779, which covers a dose of "about 2.4 mg" weekly. That case has reached a proposed joint pretrial order. In it, Novo alleges that all five of Mylan's strengths infringe.

What it does not change

Mylan still needs FDA approval. The complaint repeatedly refers to marketing "upon receipt of FDA approval," and it says Mylan received the FDA's acknowledgment of its patent challenge on Nov. 30, 2022. Reuters also reported that broader semaglutide patents expire in 2032. Winning this case would remove one patent from Mylan's path. It would not remove the others.

For investors, the new suit is Viatris clearing its path ahead of the main trial, not a sign that launch is near. Viatris shares closed up 2.35% at $17.83 on Friday, and Novo's U.S.-listed shares rose 0.47% to $38.80, according to Nasdaq data. Novo is near the bottom of its 52-week range of $35.12 to $64.16. For Viatris, a company with a market value of about $20.5 billion, even a share of a franchise this size would matter. The timetable, though, depends on the older case and the FDA, not on this filing.

For employers and benefit buyers paying for GLP-1 coverage, the practical point is the same: nothing in this filing moves the date a generic Wegovy could reach pharmacies. For more on Novo's recent deals, see our Nanexa coverage.

Sources: Mylan v. Novo Nordisk complaint, D. Del.; Reuters via Rallies; Seeking Alpha; Nasdaq market data. This is market information, not investment advice.